Response : Deferasirox ( ICL 670 ) effectively reduces liver iron concentration , whether assessed by biopsy or SQUID
نویسنده
چکیده
tion in fresh and paraffin-embedded tissue. Clin Chem. 1999;45:573574. 6. Butensky E, Fischer R, Hudes M, et al. Variability in hepatic iron concentration from percutaneous needle biopsy specimens in patients with transfusional hemosiderosis. Am J Clin Path. 2005;123:146-152. 7. Fischer R, Piga A, Harmatz P, Nielsen P. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry. Ann NY Acad Sci. 2005;1054:350-357. 8. Roper-Bouchet M, Turlin B, Graham G, et al. Drying methods affect the wet:dry weight ratio of liver tissue samples and impact liver iron content measurements [abstract]. BioIron. 2005;107. Abstract P274.
منابع مشابه
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
BACKGROUND AND OBJECTIVES Iron accumulation is an inevitable consequence of chronic blood transfusions and results in serious complications in the absence of chelation treatment to remove excess iron. Deferoxamine (Desferal, DFO) reduces morbidity and mortality although the administration schedule of slow, parenteral infusions several days each week limits compliance and negatively affects long...
متن کاملClinically Approved Iron Chelators Influence Zebrafish Mortality, Hatching Morphology and Cardiac Function
Iron chelation therapy using iron (III) specific chelators such as desferrioxamine (DFO, Desferal), deferasirox (Exjade or ICL-670), and deferiprone (Ferriprox or L1) are the current standard of care for the treatment of iron overload. Although each chelator is capable of promoting some degree of iron excretion, these chelators are also associated with a wide range of well documented toxicities...
متن کاملIron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
Patients with β-thalassemia require lifelong iron chelation therapy from early childhood to prevent complications associated with transfusional iron overload. To evaluate long-term efficacy and safety of once-daily oral iron chelation with deferasirox, patients aged ≥ 2 years who completed a 1-year, phase 3, randomized trial entered a 4-year extension study, either continuing on deferasirox (de...
متن کاملA phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
Deferasirox (ICL670) is a once-daily oral iron chelator developed for the treatment of chronic iron overload from blood transfusions. A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with beta-thalassemia aged 2 years or older. Patients were randomized and received treatment with deferasirox (n = 296) or deferoxamine (n = 290)...
متن کاملEffective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation.
Haematologica 2008;93:741-52. 2. Piga A, Fisher R, Harmatz P, St. Pierre TG, Longo F, Fung E, et al. Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with β-thalassemia, treated with deferasirox (Exjade, ICL670). Blood 2005; 106:755a. 3. Brittenham GM, Farrell DE, Harris JW, Feldman ES, Danish EH, Muir WA, et al. Magnetic-susceptibility measurement of human iro...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2006